Showing real-world impact through policy documents and clinical guidelines citations At BMJ Group, we prioritise making a tangible impact through our publications. While scholarly influence is important, its true value lies in its implications for policy and clinical guidelines, and in driving meaningful change in health and social care. In 2023, BMJ Group’s articles were cited in over 7000 policy documents and clinical guidelines, directly improving clinical practice and how health and social care is provided. This places us among the top ten most influential publishers on health and social care policy, outperforming many larger publishers in terms of the real-world impact we deliver. It also illustrates our ability to provide the best available research that resonates deeply with the clinical community. Global, rapid reach with open access I n 2019, Artificial Intelligence, Bias and Clinical Safety, 1 published in BMJ Quality and Safety , swiftly impacted global policy and practice regarding artificial intelligence (AI) in healthcare. The open access article has been cited in 24 policy documents and by 15 sources across nine countries. It has influenced reports by the European Union, the Australian Council of Learned Academies (ACOLA), and the World Health Organization (WHO). Providing open access options to the authors we work with ensures timely access to crucial research, driving the development of effective policies in fast evolving fields like AI.
Inspiring real change through global reach and recognition Typically, research takes five to 15 years to impact clinical guidelines. Various factors influence this timeline, from the quality and strength of evidence to peer review, publication, design development processes, consensus, and clinical adoption. BMJ Group’s brand recognition and global reach can accelerate this process by improving clinical practice worldwide. In less than four years, an observational study published in the Journal of Neurology, Neurosurgery & Psychiatry received 27 academic citations. It was also cited in clinical guidelines in Canada, Germany, and the Netherlands, with references from four different sources. The study, which compared outcomes after treatment with autologous haematopoietic stem cell transplantation (AHSCT) and alemtuzumab (ALZ) in patients with relapsing-remitting multiple sclerosis, was incorporated into clinical guidelines across Canada, Germany, and the Netherlands. Its influence extended beyond these countries, with references from four sources highlighting its global reach. This swift translation from research to real-world application impacted care practices in higher income countries and helped lower income regions provide more affordable care for people with multiple sclerosis.
Without open access, you miss the opportunity to expose your ideas to new communities with fresh perspectives.” Rob Challen, UK Research and Innovation AI Hub for Collective Intelligence, Engineering Mathematics, University of Bristol
85% of funded research articles published by BMJ Group in 2023 were open access
Powered by FlippingBook